Zobrazeno 1 - 10
of 39
pro vyhledávání: ''
Autor:
Xiaojing Zhang, Zhiqiang Meng, Shanzhi Gu, Shukui Qin, Zhendong Chen, Xiao Zhang, Linna Wang, Xinni Chen, Jianjun Zou, Ying Liu, Jianping Xiong, Zhenggang Ren
Publikováno v:
International Journal of Cancer. 149:1944-1954
Biliary tract cancer (BTC) is a highly malignant tumor with limited treatment options and poor prognosis. Our study aimed to evaluate camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced BTC. In this multicenter, open-l
Autor:
Carla Verena Hannig, Thomas R. W. Herrmann, Lukas Perkhofer, Thomas J. Ettrich, Thomas Seufferlein, Petra Büchner-Steudel, Andreas Berger, Patrick C. Hermann, Holger Hebart, Thomas J. Hoffmann, Thomas Decker, Volker Heinemann, M Güthle, Ralf-Dieter Hofheinz
Publikováno v:
International Journal of Cancer. 148:1428-1437
Nintedanib is a triple angiokinase inhibitor of vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-3 and platelet-derived growth factor receptor-a/-b. Thereby, it targets angiogenic escape mechanisms. The trial TyRos
Autor:
Jeong Won Jang, Sun Hong Yoo, U Im Chang, Hee Yeon Kim, Seung Kew Yoon, Do Seon Song, Sang Wook Choi, Jong Young Choi, Chang Wook Kim, Sung Won Lee, Kwon Yong Tak, Seok Hwan Kim, Pil Soo Sung, Hae Lim Lee, Jung Hyun Kwon, Myeong Jun Song, Jin Mo Yang, Hee Chul Nam
Publikováno v:
International Journal of Cancer. 147:1970-1978
Controlling adverse events (AEs) through dose reduction can enhance drug adherence and treatment response. Currently, there is no guide for sorafenib dosing. The aim of this study was to evaluate whether sorafenib dosing could affect treatment outcom
Autor:
Takeshi Terashima, Noriho Iida, Jun Seishima, Shuichi Kaneko, Tatsuya Yamashita, Kuniaki Arai, Eishiro Mizukoshi
Publikováno v:
International Journal of Cancer
Overuse of antibiotic drugs alters the composition of gut microbiota and has detrimental effects on the host. In our study, we investigated association of gut flora and antibiotics in the prognosis of patients with liver cancer who have undergone che
Autor:
Jean-Yves Douillard, Dominik Paul Modest, Jean-Baptiste Bachet, Fernando Rivera, Gaston Demonty, Reija Koukakis, Filippo de Braud, Filippo Pietrantonio
Publikováno v:
International Journal of Cancer
International Journal of Cancer, Wiley, 2019, 145 (2), pp.576-585. ⟨10.1002/ijc.32110⟩
International Journal of Cancer, Wiley, 2019, 145 (2), pp.576-585. ⟨10.1002/ijc.32110⟩
Panitumumab is approved for RAS wild‐type metastatic colorectal cancer and was evaluated in Phase III (PRIME, NCT00364013) and Phase II (PEAK, NCT00819780) first‐line randomised studies. This retrospective analysis of these trials investigated ef
Autor:
Antonio Cubillo, Elena Poddubskaya, Nebojsa Manojlovic, Jean-Luc Canon, Pascal Hammel, Eric Van Cutsem, Manuel Hidalgo, Teresa Macarulla, C. Zhao, Armin Schueler, Igor Bazin, Eric Raymond, Dejan Radenkovic, Chris Verslype
Publikováno v:
International Journal of Cancer. 143:2053-2064
The selective MEK1/2 inhibitor pimasertib has shown anti-tumour activity in a pancreatic tumour model. This phase I/II, two-part trial was conducted in patients with metastatic pancreatic adenocarcinoma (mPaCa) (NCT01016483). In the phase I part, ora
Autor:
Andreas Jung, Markus Moehler, Werner Scheithauer, Tobias Heintges, Jobst C. von Einem, Martina Stauch, Christoph Kahl, Frank Kullmann, Swantje Held, Alexander Kiani, Thomas Kirchner, Salah-Eddin Al-Batran, Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Fire study investigators, Sebastian Stintzing, Ursula Vehling-Kaiser, Dominik Paul Modest, Christian A. Lerchenmuller, G. Seipelt
Publikováno v:
International Journal of Cancer. 140:1918-1925
We explored the association of early tumor shrinkage (ETS) and non-ETS with efficacy of first-line and consecutive second-line treatment in patients with KRAS wild-type metastatic colorectal cancer treated in FIRE-3. Assessment of tumor shrinkage was
Autor:
James J. Lee, Colin D. Weekes, Heinz-Josef Lenz, A. Craig Lockhart, Isrid Sturm, Funan Huang, Adriaan Cleton
Publikováno v:
International Journal of Cancer
Regorafenib 160 mg orally once daily (QD) 3 weeks on/1 week off is approved in colorectal cancer, gastrointestinal stromal tumors and hepatocellular carcinoma. We established the safety and pharmacokinetics (PK) of regorafenib combined with cetuximab
Autor:
Peter Møller, Alfred C. Feller, Norbert Schmitz, Hanne Helfrich, Markus Kreuz, Martin-Leo Hansmann, Lorenz Trümper, Andreas Rosenwald, Stephan Stilgenbauer, Harald Stein, Thorsten Zenz, Doris Winter, Maxi Fuge, Annette M. Staiger, Markus Loeffler, Wolfram Klapper, Michael Pfreundschuh, Heike Horn, Reiner Siebert, Jennifer Huellein, German Ott
Publikováno v:
International journal of cancer. 141(7)
TP53 is mutated in 20%-25% of aggressive B-cell lymphoma (B-NHL). To date, no studies have addressed the impact of TP53 mutations in prospective clinical trial cohorts. To evaluate the impact of TP53 mutation to current risk models in aggressive B-NH
Autor:
A Nour‐Eldin Nour‐Eldin, Jörg Trojan, Marc Harth, Hanns Ackermann, Nagy N.N. Naguib, Thomas J. Vogl, Boris Schulz, Martin Beeres, Katrin Eichler, Stephan Zangos, Tatjana Gruber-Rouh
Publikováno v:
International Journal of Cancer. 134:1225-1231
The aims of the study were to evaluate therapeutic efficacy and to determine the prognostic factors for treatment success in patients with liver metastases from colorectal cancer (CRC) treated with transarterial chemoembolization (TACE). A total of 5